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Previous studies from our laboratory showed that increased
fatty acid oxidation by the kidney is cytoprotective during
cisplatin (CP)-mediated nephrotoxicity. In this study, we
determined the effects of CP and fibrates on peroxisome
proliferation and the expression of liver fatty acid-binding
protein (L-FABP) in normal mice, and in mice transgenically
overexpressing human L-FABP (h-L-FABP). Labeling of
peroxisomes demonstrated reduced peroxisomal staining in
the proximal tubule of CP-treated mice compared with
control mice. There was increased peroxisomal labeling in
the proximal tubules of both control and CP-treated mice
when either was treated with fibrate; a known peroxisome
proliferator-activated receptor-a ligand. L-FABP protein
expression, not detected in control or CP-treated mice, was
significantly increased in the proximal tubules of fibrate-
treated mice of either group. In the transgenic mice, CP
increased the shedding of h-L-FABP in the urine, which was
decreased by fibrate as was the acute renal failure.
A cytosolic pattern of h-L-FABP expression was found in
the proximal tubules of untreated transgenic mice with a
nuclear presence in CP-treated mice. Fibrate pretreatment
restored the cytosolic expression pattern in CP-treated mice.
Our study shows that fibrate may improve CP-induced
acute renal failure due to both peroxisome proliferation and
increased L-FABP in the cytosol of the proximal tubule.
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The intracellular fatty acid-binding proteins (FABPs) belong
to a super family of lipid-binding proteins with low
molecular weight (14–15 kDa), which are classified according
to their predominant tissue localization. There are nine
different FABPs, with tissue-specific distribution that include
L (liver), I (intestinal), H (muscle and heart), A (adipocyte),
E (epidermal), Il (ileal), B (brain), M (myelin), and
T (testis).1 The liver isoform of FABP (L-FABP) is highly
expressed in hepatocytes, where it represents 5% of the total
cytosolic protein. L-FABP facilitates the cellular uptake,
transport, and metabolism of fatty acids, and is also involved
in the regulation of gene expression and cell differentia-
tion.2–5 Previous work in liver tissue has shown (1) that the
level of L-FABP expression in rodent liver is regulated in
concert with peroxisome proliferation and (2) that the
transcription rate of L-FABP gene is regulated and induced
by both fibrate hypolipidemic drugs and long-chain fatty
acids, through a peroxisome proliferator-activated receptor
(PPAR)-responsive element located in its promoter region.6,7
Although the kidney in rodents does not synthesize a
significant amount of L-FABP protein,8 recent work suggests
that L-FABP under normal conditions resides in the
lysosomal compartment of the proximal tubule, but also
can be reabsorbed from the glomerular filtrate via megalin, a
multiligand proximal tubule endocytic receptor.9 On the
other hand, the amount of L-FABP protein present in human
kidney is considerably much higher than the amount of
L-FABP protein present in rodent kidney tissue, and its
expression is restricted to the proximal convoluted and
straight tubules.10,11 In more recent studies using human
L-FABP (h-L-FABP) transgenic mice, which express higher
protein levels of h-L-FABP in proximal tubules when
compared with non-transgenic mice, Noiri et al.12,13 demons-
trated that the shedding of h-L-FABP was increased in urine
obtained from mice that underwent ischemia–reperfusion
injury. Immunohistochemical analysis of kidney tissue of
h-L-FABP transgenic mice subjected to ischemia–reperfusion
injury demonstrated increased translocation of h-L-FABP
from the cytoplasm of the proximal tubule to the tubular
lumen. In addition, renal function and histological scores of
acute kidney injury, in h-L-FABP transgenic mice subjected
to ischemia–reperfusion injury, were significantly ameliorated
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when compared with wild-type mice. The role of L-FABP in
acute kidney injury caused by cisplatin (CP) has not been
examined previously.
In previous studies, we have documented that the
inhibition of peroxisomal and mitochondrial fatty acid
oxidation (FAO) observed in kidney tissue of mice under-
going ischemia–reperfusion injury and CP-induced acute
renal failure (ARF) results from reduced activity of
PPARa.14–20 Failure to oxidize long-chain fatty acids and
long-chain acylcarnitines during ARF results in their
accumulation and cellular toxicity, which further contributes
to proximal tubule cell death.21,22 In a recent metabolomic
study,23 we found that CP-mediated nephrotoxicity was
accompanied by increased serum levels of nonesterified fatty
acids and triglycerides, as well as increased accumulation of
nonesterified fatty acids and triglycerides in kidney tissue. We
also observed that the administration of fibrate, a known
PPARa ligand, before ARF (1) prevented the inhibition of
FAO and the accumulation of nonesterified fatty acids and
triglycerides in kidney tissue, and (2) ameliorated apoptotic
and necrotic proximal tubule cell death, which resulted in
significant protection of renal function only in PPARa wild-
type mice, and not in PPARa null mice.17–20 Altogether, these
previous observations from our laboratory suggest that
increased FAO, via PPARa activation, plays a significant role
in the observed cytoprotection by fibrates in CP-mediated
nephrotoxicity. The cellular targets by which increased
PPARa activity in kidney tissue prevents ARF after CP
exposure are not currently known.
In these studies, we investigated the contribution of
peroxisome proliferation and L-FABP protein expression to
the cytoprotective effect of fibrates in the CP model of ARF.
For these studies, we used sv-129 mice as well as h-L-FABP
transgenic mice. We examined the effects of CPþ fibrate on
L-FABP expression in kidney tissue and on the shedding of
urinary h-L-FABP. In addition, we performed immunohisto-
chemical studies to examine the effects of CPþ fibrate on
peroxisome proliferation, and the intracellular localization of
L-FABP in kidney tissue, and correlated with effects on renal
function.
RESULTS
Studies in sv129 mice
Protective effects of PPARa ligand on CP-induced ARF. Kidney
function was monitored by measuring blood urea nitrogen
(BUN) and serum creatinine for 3 days after intraperi-
toneal injection of saline (groups: control and WY) or CP
(groups: CP and CPþWY). Figure 1a and b present the
changes on BUN and creatinine in mice treated with saline
(control), CP, and with WY in the presence of CP. Mice
treated with a regular diet and CP developed ARF at day 3
(BUN increased from 28 to 135 and creatinine increased from
0.2 to 1.2 mg/dl). The group of mice that received the WY
diet and CP did not develop significant ARF when compared
with mice treated with CP alone (BUN increased from 24 on
day 1 to 32 and creatinine was unchanged at 0.2 mg/dl after 3
days of CP administration). By contrast, the protective effect
of the ligand was lost in PPARa null mice treated with CP
(data not shown). PPARa null mice pretreated with a fibrate
diet before CP administration developed ARF at day 3. BUN
increased from 30 at day 1 to 186 at day 3 and creatinine
increased from 0.3 at day 1 to 1.5 mg/dl at day 3.
Effects of CPþ fibrates on the expression of 70-kDa peroxi-
somal membrane protein and peroxisomal matrix protein
catalase. We examined by Western blot analysis whether
CP or fibrate (WY) treatment had an effect on protein levels
of 70-kDa peroxisomal membrane protein (PMP70) or
catalase. As shown in Figure 2a, CP-treated mice exhibited
a time-dependent reduction in PMP70 protein levels. PMP70
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Figure 1 | Effect of fibrate WY-14643 (WY) on renal function in
mice after single dose of CP. Mice were fed with either a regular
diet or a diet containing 0.1% WY for 7 days before CP administration,
as described in Materials and Methods. BUN and creatinine levels
were measured at days 1, 2, and 3 after saline (control)-, CP-, or
CPþWY-treated mice. Bars correspond to mean7s.e. of at least six
independent experiments under each condition. Changes in (a) BUN
and (b) creatinine levels, respectively, after saline or CP
administration in PPARa wild-type mice. *Po0.005 when animals
were compared with control by unpaired Student’s t-test.
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protein levels were reduced by 50% at day 2 and by 75% at
day 3 after CP injection. As our studies have shown that the
use of PPARa ligand-like fibrates prevent the development of
CP-induced proximal tubule cell death by preventing the
inhibition of FAO,14,17 we next examined the effect of fibrate
on PMP70 protein levels. As shown in Figure 2b, at day 3
after CP injection, there was a 75% reduction in PMP70
protein levels. In contrast, the group of mice that received the
diet containing the fibrateþCP exhibited increased levels of
PMP70 by 1.5-fold for fibrate alone, and 1.5-fold for
fibrateþCP-treated mice when compared with control
untreated mice. We also measured by Western blot analysis
protein levels of catalase, a peroxisomal matrix protein. CP at
day 3 caused a 30% reduction in expression of a 60-kDa
protein corresponding to catalase, and fibrateþCP signifi-
cantly increased catalase protein expression to levels similar
to the ones observed in control untreated mice, as shown in
Figure 3.
Image analysis of quantum dot peroxisome fluorescence from
kidneys of fibrate-treated mice. To determine the effects of
CPþ fibrate on peroxisome proliferation, we used a recently
developed method for immunofluorescent staining of
peroxisomes and quantification of peroxisome fluorescence
using an antibody to the PMP70 coupled with fluorescent
nanocrystals, Quantum DotsTM.24 The quantum dot peroxi-
some fluorescence information is contained in the red
channel of the RGB image, so quantification is performed
in the red channel using a confocal microscope. As shown in
Figure 4a, the pixel intensity of red/orange quantum dots was
predominantly observed in the proximal tubules of control
untreated mice (15 10371406 pixel fluorescent units) and
was significantly elevated in fibrate (WY)-treated mice
(21 10371256 pixel fluorescent units; Figure 4b). The
intensity of pixels was significantly reduced in CP-treated
animals (1.7 1037803 pixel fluorescent units; Figure 4c)
when compared with fibrate (WY)þCP-treated mice
19 10371167 pixel fluorescent units; Figure 4d). Figure
4e summarizes data obtained from four separate experi-
ments.
Effect of CP on mouse L-FABP mRNA levels in kidney tissue of
sv129 mice. We next examined the effects of CP on mRNA
expression of mouse L-FABP (mL-FABP) in kidney tissue of
sv129 mice. As shown in Figure 5, by real-time reverse
transcriptase-polymerase chain reaction quantitative analysis,
after 3 days of CP injection, there was a mild (1.5–1.8-fold)
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Figure 2 | Effect of fibrate and cisplatin on PMP70 expression in
kidney tissue. (a) Time course of the effect of CP on PMP70 protein
expression in kidney tissue. Mice were administered saline (control)
or CP (20 mg/kg body weight) by a single intraperitoneal injection.
Western blot analysis of kidney tissue homogenates at days 1, 2, and
3 after CP injection using a PMP70 antibody as described in Materials
and Methods. Bars correspond to mean7s.e. of at least three
independent experiments under each condition. (b) Effect of fibrate
(WY) and CP on PMP70 protein expression. Mouse kidney tissue
homogenates were prepared from animals subjected to four
experimental conditions, and Western blots were performed as
described in Materials and Methods. PMP-70 protein levels were
normalized using b-actin as internal control. Bars correspond to
mean7s.e. of at least three independent experiments under each
condition.
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Figure 3 | Effect of fibrate (WY) and CP on catalase protein
expression. Mouse kidney tissue homogenates were prepared from
animals subjected to four experimental conditions, and Western blots
were performed as described in Materials and Methods. Catalase
protein levels were normalized using b-actin as internal control.
Bars correspond to mean7s.e. of at least three independent
experiments under each condition.
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increase in the mL-FABP mRNA levels when compared with
saline-treated mice. In kidney tissue of sv129 mice treated
with CPþ fibrate, there was a 3.0-fold increase on L-FABP
mRNA levels (Po0.01), and fibrate alone upregulated
L-FABP mRNA expression by fivefold (Po0.01) when
compared with saline-treated mice.
Fibrate increases L-FABP protein expression in kidney tissue of
PPARa wild type but not on PPARa null mice. Using antibodies
that recognize mL-FABP and kidney tissue isolated from
sv129 mice treated with CPþ fibrate (WY), we found that
protein expression of mL-FABP, which was not detected in
kidney tissue of untreated or CP-treated sv129 mice, was
significantly induced in the proximal tubules of PPARa wild-
type mice treated with the fibrate, in the absence and
presence of CP. Western blot analysis of mL-FABP, shown in
Figure 6a, demonstrates that L-FABP protein was not
detected in control or CP-treated sv129 mice. However,
treatment of sv129 mice with PPARa ligand WY led to a
rapid increase in the expression of mL-FABP. Even though
CP treatment slightly reduced expression of L-FABP protein
level, it remained significantly elevated in the presence of
PPARa ligand WY. By contrast, mL-FABP expression was not
detected in kidney tissue of PPARa null mice treated with
fibrates, where we did not see protection from CP-induced
ARF, as shown in Figure 6b.
Immunohistochemical localization of mL-FABP. Immuno-
histology of normal mouse kidney cortex demonstrated no
positive L-FABP staining (Figure 7a). As shown in Figure 7b,
L-FABP is highly expressed in Bowman capsule and early
proximal tubule cells of WY-treated animals. In fibrate-
treated sv129 mice, a strongly positive staining was seen in
the cytosol and perinuclear localization. Only occasional,
single cell-positive staining could be seen in CP-treated
animals in intact proximal tubules (Figure 7c). Similarly to
the WY-treated animals, the positive L-FABP immunoreac-
tivity was detected in Bowman capsule and early proximal
tubule cells in kidneys from WYþCP-treated mice (Figure
7d). There was no positive staining in glomeruli and distal
nephron segments.
Studies in h-L-FABP transgenic mice
Effects of CPþ fibrate on renal function in h-L-FABP transgenic
mice. To further examine the regulation of L-FABP expres-
sion in mouse kidney tissue, we used h-L-FABP transgenic
mice. These mice express higher levels of h-L-FABP protein
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Figure 4 | Effect of fibrate (WY) and CP on peroxisomal
distribution. (a) Mouse kidney sections from animals subjected to
four experimental conditions (a) control, (b) fibrate (WY), (c) CP, and
(d) WYþCP were stained with PMP70 antibody as described in
Materials and Methods. (e) Quantitative analysis of pixel densities of
the peroxisomal population present in the four experimental
conditions was performed as described in the Materials and Methods
section. Bars correspond to mean7s.e. of at least four independent
experiments under each condition.
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Figure 5 | Effect of CP and fibrate on mL-FABP mRNA levels in
SV-129 wild-type mice. Mice that received either a normal diet or
a diet containing fibrate (WY) for 7 days were injected with saline
(control) or CP and then killed at the indicated times. Levels of
mL-FABP mRNA was measured by real-time reverse transcriptase-
polymerase chain reaction as described in Materials and Methods.
Figure shows relative mL-FABP gene expression in saline (control),
CP-, CPþ fibrate-, and fibrate-treated mice normalized by 28S
rRNA expression. Values are mean7s.e. mRNA levels. Data were
obtained from at least three independent experiments.
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in the cytosolic compartment of the proximal tubule when
compared with non-transgenic mice, and do not exhibit a
particular histologic or functional renal phenotype. In
previous published studies using these same h-L-FABP
transgenic mice, Noiri13 and Kamijo et al.25 demonstrate
that acute kidney injury due to ischemia–reperfusion injury
and unilateral ureteral obstruction was significantly amelio-
rated when compared with wild-type non-transgenic mice.
CP was administered at a dose of 20 mg/kg body weight, and
fibrate was administered as a diet containing 0.5% bezafibrate
(Bz) for 7 days before the administration of CP. Figure 8a and
b present the changes on BUN and creatinine in h-L-FABP
transgenic mice treated with saline (control), CP, and with Bz
in the absence and presence of CP. Mice treated with a regular
diet and CP developed ARF at day 3 (BUN increased from 24
to 143 and creatinine increased from 0.15 to 1.50 mg/dl). The
group of mice that received the Bz diet and CP were
significantly protected from CP nephrotoxicity, when com-
pared with mice treated with CP alone (BUN increased from
24 to 62 and creatinine increased from 0.15 to 0.47 mg/dl).
Effect of CPþ fibrate on shedding of urinary h-L-FABP. In
h-L-FABP transgenic mice treated with CP, analysis of urinary
h-L-FABP protein by enzyme-linked immunosorbent assay
demonstrated a time-dependent increase in the shedding of
urinary h-L-FABP protein, which was detected within the
first 24 h after CP administration (n¼ 12). Figure 9 shows the
time course of shedding of urinary h-L-FABP after CP or
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Figure 6 | Effect of CP and Wy on L-FABP protein levels in SV-129
wild-type (þ /þ ) and PPARa null (/) mice. (a) Effect f of CP and
WY on L-FABP protein levels in SV-129 wild-type (þ /þ ) mice. The
immunoblot analysis of mouse kidney tissue homogenates from four
different experimental conditions was performed as described in
Materials and Methods. b-Actin antibody was used as an internal
control for normalizing the L-FABP protein levels. Bars correspond to
mean7s.e. of at least three independent experiments under each
condition. *Po0.005 when animals were compared with control by
unpaired Student’s t-test. (b) Effect f of CP and fibrate on L-FABP
protein levels in sv-129 PPARa knock out (/) mice. The
immunoblot analysis of mouse kidney tissue homogenates from four
different experimental conditions was performed as described in
Materials and Methods. Kidney homogenate from wild-type mice
treated with fibrate (WY) was run as positive control for L-FABP
protein. b-Actin antibody was used as an internal control for
normalizing the L-FABP protein levels.
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Figure 7 | Immunolocalization of mL-FABP. Representative picture
of kidney sections from (a) control-, (b) fibrate (WY)-, (c) CP-, and
(d) WYþCP-treated mice stained with anti-mL-FABP antibody.
Positive immunostaining was apparent only in fibrate and
fibrateþCP-treated mice predominantly in proximal tubules (PT)
of the outer cortex (arrows). Original magnification  122.
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Figure 8 | Effect of Bz on renal function in h-L-FABP transgenic
mice after single dose of CP. Mice were fed with either a regular
diet or a diet containing 0.1% Bz for 7 days before CP administration,
as described in Materials and Methods. BUN and creatinine levels
were measured at days 1, 2, and 3 after saline control (NS)-, CP (CP)-,
CPþ Bz (CPþ BZ)-, or salineþ Bz (BZþNS)-treated mice. Bars
correspond to means7s.e. of at least 10 independent experiments
under each condition. (a) Changes in BUN and (b) creatinine levels,
respectively, after saline or CP administration in PPARa wild-type
mice. *Po0.05 when CPþ Bz group was compared with CP alone
group by unpaired Student’s t-test.
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saline administration. In CP-treated h-L-FABP transgenic
mice, urinary h-L-FABP levels increased by 100-fold at day 1
after CP injection, from baseline levels of 13.6 mg/g creatinine
in saline-treated mice to 1334.9 mg/g creatinine in CP-treated
mice. At 3 days after CP injection, urinary h-L-FABP levels
did increase by 647-fold from baseline level of 12.9–8422 mg/g
creatinine. Urinary levels of h-L-FABP were significantly
reduced in the BzþCP-treated group when compared with
CP-treated mice (urinary h-L-FABP levels were reduced from
8422 to 1120mg/g creatinine at day 3 after CP administra-
tion). Statistical significance between different time points in
the same group was evaluated by paired t-test, and the
statistical significance between two separate groups was
evaluated by analysis of variance. Our results suggest that
the increased shedding of h-L-FABP protein in urine samples
obtained from CP-treated h-L-FABP transgenic mice pre-
cedes changes in serum creatinine or BUN, which were not
detected until 2–3 days after CP administration as shown in
Figure 8. Our results also show that very small amounts of
urinary h-L-FABP are also shed by the administration of a
PPARa ligand.
Immunohistochemical localization of h-L-FABP in h-L-FABP
transgenic mice. There was no positive immunoreactivity for
h-L-FABP in kidneys from control C57Bl wild-type non-
transgenic mice (Figure 10a). Untreated h-L-FABP transgenic
animals showed strong positive staining in the cytoplasm of
early (S1 and S2) segments of proximal tubules, with
occasional strong perinuclear appearance (Figure 10b). In
kidney tissue of h-L-FABP transgenic mice, CP administra-
tion caused a positive nuclear staining for h-L-FABP in the
epithelium of Bowman capsule and early (S1 and S2)
segments of proximal tubules (Figure 10c). The BzþCP-
treated mice showed strong cytoplasmic staining in proximal
tubules of the deep cortex (S3 segment; Figure 10d).
Glomeruli and distal nephron segment were mainly negative.
Morphologic changes of kidneys from h-L-FABP transgenic
mice after CP treatment with and without Bz pretreatment. CP-
treated h-L-FABP transgenic mice showed severe tubular
necrosis in the outer cortex (primarily S1 and S2 segments of
proximal tubule). Necrosis was accompanied by loss of brush
border; tubular dilatation, and numerous casts (Figure 11a).
Necrosis was markedly reduced in h-L-FABP transgenic
animals, which were pretreated with Bz before CP adminis-
tration (Figure 11b). Proximal tubules in the corticomedul-
lary junction (primarily S3 segments of proximal tubule)
were dilated, contained periodic acid-Schiff (PAS)-positive
proteinous casts, and their cytoplasm was filled with PAS-
positive droplets (Figure 11c). Few animals showed signs of
mild to rarely moderate degree of necrosis and tubular
dilatation, loss of brush border, cast formation, which were
occasionally present in the outer cortex. Proximal tubules in
the corticomedullary junction had no signs of dilatation, loss
of brush border, and cast formation. The PAS-positive
droplets present in the CP-treated mice were missing after
Bz pretreatment (Figure 11d). Interstitial inflammation,
edema, red blood cell extravasation, or distal nephron
segment damage were not seen. Morphologic changes were
quantified and the results are shown in Figure 11e.
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Figure 9 | Effect of BZ on urinary h-L-FABP levels after single
dose of CP. Urinary h-L-FABPlevels were measured at days 1, 2,
and 3 after saline control (NS)-, CP (CP)-, CPþ BZ (CPþ BZ)-, or
salineþ Bz (BZ)-treated mice by enzyme-linked immunosorbent assay
as described in Materials and Methods. * Represents Po0.05 when
urinary h-L-FABP levels were compared at day 3 and day 2 after
CP administration. ** Represents Po0.05 when urinary h-L-FABP
levels were compared at day 2 versus day 1 and day 0, and
# represents Po0.05 when urinary h-L-FABP levels were compared
among all the four groups. Bars correspond to mean7s.e. of at least
seven independent experiments under each condition.
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Figure 10 | Immunolocalization of h-L-FABP in h-L-FABP
transgenic mice. (a) There was no positive immunoreactivity for
h-L-FABP in kidneys from control C57Bl wild-type non-transgenic
mice. (b) Untreated h-L-FABP transgenic animals showed strong
positive staining in the cytoplasm of early (S1 and S2) segments of
proximal tubules (PT). (c) CP administration caused a positive nuclear
staining for h-L-FABP in the epithelium of Bowman capsule and
early (S1 and S2) segments of proximal tubules (PT) (arrows). (d)
The BzþCP-treated mice showed strong cytoplasmic staining in
proximal tubules (PT) of the deep cortex (S3 segment) (arrows).
Glomeruli (G) and distal nephron segment were mainly negative.
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DISCUSSION
In this study, we demonstrate that CP causes a significant
reduction in the peroxisome population of the proximal tubule
determined by reduced protein expression of PMP70, and by
quantification of peroxisomes using quantum dot technique.
Our findings in the CP model of ARF are in agreement with
findings described in the ischemia–reperfusion model of ARF,
where a significant loss of catalase and fatty acid b-oxidation
enzymes were accompanied by reduced number of peroxisomes
in kidney tissue.26 The mechanisms responsible for the
degradation of peroxisomal proteins during ARF are unclear,
but could involve autophagy, a global process by which
intracellular components including soluble proteins and orga-
nelles, are degraded in lysosomes.27–29 The presence of lysosomes
containing microautophagic vacuoles has been reported pre-
viously in rat proximal tubules of animals treated with
vinblastine;30 however, the pathogenic role of these structural
alterations in CP-mediated ARF remains to be defined.
Our studies showing a PPARa ligand-like fibrate increases
the expression of peroxisomal proteins in mouse kidney
tissue suggest that the presence of increased peroxisome
proliferation in the proximal tubule is associated with
cytoprotection. Peroxisome proliferation can also be seen in
liver tissue of rats treated with hypolipidemic drugs such as
fibrates, and it is accompanied by increased FAO.31 Peroxi-
somes are organelles bound by a single membrane that are
involved in metabolic processes including peroxide-based
respiration, oxidative degradation of fatty acids and purines,
and synthesis of plasmalogen and bile acids.32,33 FAO is an
important source of energy, especially during fasting,
diabetes, or ARF.34 Although mitochondria are considered
the primary site for b-oxidation of fatty acid for energy
utilization, it is now well established that peroxisomes play a
key role in the metabolism of a variety of lipids such as very
long-chain fatty acids, branched-chain fatty acids, dicar-
boxylic acids, prostaglandins, leukotrienes, thromboxanes,
and pristanic acid.35 In addition, the functional importance
of peroxisomes is underscored by the severity of peroxisomal
disorders such as Zellweger syndrome, X-linked adrenoleu-
kodistrophy, and Refsum disease.36
Role of L-FABP in CP-induced ARF
Our study is the first one to examine the role of L-FABP in
the model of CP-induced ARF. The family of fatty acid-
binding proteins, which was initially discovered in 197237 is
composed of small cytosolic proteins that are part of a
conserved multigene family of intracellular lipid-binding
proteins with molecular masses around 15 kDa. Two distinct
isoforms of FABPs are expressed in kidney tissue the heart
isoform, which is expressed in distal tubules and the liver
(L-FABP) isoform, which is expressed in the proximal tubule.38
FABPs are involved in the transport of free fatty acids from
the plasma membrane to sites for oxidation (mitochondria
and peroxisomes), sites for esterification into triacylglycerols
or phospholipids, and the nucleus for gene regulation. Liver-
type FABP found in kidney proximal tubules binds with
other hydrophobic molecules such as lysophospholipids,
eicosanoids, bile acids, bilirubin, heme, and hypolipidemic
drugs,39–41 and thus protects cellular structures from damage
by an excess of these amphipatic molecules. Early studies by
Gordon et al.8 using transgenic mice to map cis-acting
elements in the L-FABP gene indicated that nucleotides
4000 to þ 21 of mL-FABP contain orientation-indepen-
dent suppressor sequences, which can make L-FABP to
remain silent for at least the first year of postnatal life in renal
proximal tubular cells of Sprague–Dawley rats and C57Bl/6
mice. We find that although L-FABP mRNA levels were
slightly elevated in kidney tissue of CP-treated sv129 mice,
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Figure 11 | Effect of Bz on kidney morphology in h-L-FABP
transgenic mice after single dose of CP. Kidney morphology of
h-L-FABP transgenic mice after 72 h of (a and c) CP exposure and
after treatment with (b and d) BzþCP. Severe tubular necrosis was
seen in the proximal tubules (S1 and S2) of the outer cortex of
(a) CP-treated mice (*). Bz significantly ameliorated necrosis of
proximal tubules (PT) caused by (b) CP injection. Proximal tubules of
the deep cortex (S3 segment) (PT) showed PAS-positive droplet
accumulation in their cytoplasm in (c) CP-treated mice (arrows),
which was ameliorated by (d) Bz pretreatment (arrows).
(e) Quantitative evaluation of morphologic kidney damage of
h-L-FABP transgenic mice after CP and BzþCP. Values are
expressed as relative severity on a scale from 0 to 4 and represent
mean7s.e. of kidney sections from at least eight mice for each
experimental condition. Morphology was scored according to
proximal tubule necrosis (Necrosis), brush border loss (BB Loss), cast
formation within tubules (Casts), tubule dilation (Dilatation), and
tubular degeneration (Degen). Statistically significant differences
(Po0.05) are indicated.
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L-FABP protein was not found increased in kidney tissue of
wild-type sv129 mice by either Western blot analysis or
immunohistochemical studies. In contrast, treatment with
fibrate significantly increased the expression of L-FABP
protein when compared with untreated mice, and L-FABP
was predominantly localized in the proximal tubule of sv-129
wild-type mice, and absent in PPARa null mice, demon-
strating that the increased expression of L-FABP in kidney
tissue of sv129 depends on having an intact PPARa gene.
Our studies using h-L-FABP transgenic mice to examine
the pathophysiologic mechanisms involved in CP-induced
ARF did allow us to uncover some important observations,
which were not readily apparent when we examined kidney
tissue of sv129 mice exposed to CP. The first one is that CP
causes a translocation of h-L-FABP protein from the cytosolic
to the nuclear compartment of proximal tubules, as shown by
our immunohistochemistry studies. The effects of CP in the
cellular localization of h-L-FABP could not be studied in
sv129 mice because these mice do not express significant
amounts of L-FABP protein. It is unclear at the moment the
mechanisms that could account for the observed changes in
cellular localization of h-L-FABP during CP treatment;
however, future studies using immunoprecipitation and/or
immunofluorescence localization using either intact kidney
tissue of h-L-FABP transgenic mice or proximal tubules
derived from these mice could provide additional informa-
tion regarding the cellular processes and potential protein(s)
involved in the regulation and/or cellular translocation of
h-L-FABP during proximal tubule cell injury.
Second important observation in h-L-FABP transgenic
mice was that h-L-FABP protein was shed into the urinary
space early in the course of CP-induced kidney injury. Our
studies using enzyme-linked immunosorbent assay methods
to measure h-L-FABP protein levels allowed us to detect early
shedding of h-L-FABP during the first 24 h of CP exposure,
which precedes the rise on serum BUN and creatinine not
detected until after 48–72 h of CP exposure. These studies
suggest that shedding of h-L-FABP could represent an early
urine biomarker of CP-mediated nephrotoxicity. Recently
Dr Noiri and Dr Sugaya from the University of Tokyo using
the model of human kidney transplantation, and more
recently h-L-FABP transgenic mice and the model of 30-min
ischemia–reperfusion injury demonstrated that reduced
pericapillary blood flow detected by intravital CCD system
was closely correlated with ischemic time of transplanted
kidney. Interestingly, these investigators also detected the
translocation of h-L-FABP protein from the cytoplasm of the
proximal tubule to the tubular lumen by immunohisto-
chemistry.13 The mechanisms by which h-L-FABP is shed
into the urinary space are currently unknown, but could
involve disruption by CP of proximal tubule endocytic
mechanisms via megalin receptor. A recent study documen-
ted that L-FABP is localized to the lysosomal compartment of
the proximal tubule, but also reabsorbed from the glomerular
filtrate via megalin receptor-mediated endocytosis.9 In
addition, studies using kidney-specific megalin receptor
knockout mice suggest that other lipid-binding proteins
such as apolipoprotein M, which is also reabsorbed in the
proximal tubule via megalin receptor-mediated endocytosis,
is also shed into the urinary space.42 Our most recent
findings of increased shedding of apolipoprotein M in mice
that received CP suggest that disruption of megalin receptor-
mediated endocytosis by CP could represent one of the
mechanisms by which h-L-FABP protein and other lipocalins
could be shed into the luminal space during ARF.
Third important observation made in h-L-FABP trans-
genic mice was that fibrate pretreatment prevented
CP-mediated shedding of urinary h-L-FABP, CP-mediated
translocation of proximal tubule h-L-FABP from the cytosol
to the nuclear compartment, and also significantly amelio-
rated CP-induced acute kidney failure by reducing necrosis,
brush border loss, and other parameters of proximal tubule
cell injury. The increased cytosolic localization of h-L-FABP
in proximal tubules of fibrate-treated mice is consistent with
recent observations made in Sprague–Dawley rats treated
with fibrates, where the authors demonstrated the presence of
L-FABP in the matrix of liver peroxisomes.5 The induction of
peroxisomal L-FABP in rat liver tissue was accompanied by
increased binding to oleic acid and cisparinaric acid, and
increased b-oxidation of palmitoyl CoA and acyl CoA
esterase activity, indicating that this protein modulates the
function of peroxisomal lipid-metabolizing enzymes.
Altogether, our results underscore the participation of
peroxisomes in the pathophysiology of CP-mediated nephro-
toxicity, and the protective role of their induction via fibrates in
limiting proximal tubule cell death and organ dysfunction.
However, it is difficult to dissect out a single role of peroxisomes
in the prevention of CP-mediated organ dysfunction, since
fibrates via PPARa activation induce not only peroxisomal
proteins, but also affect the transcription of other genes such as
those of mitochondrial and microsomal enzymes as well.
Furthermore, our previous studies also suggest a protective role
of PPARa ligands on renal function by preventing not only
inflammation,19 but also by reducing systemic and renal
alterations in glucose and lipid metabolism caused by CP.23 In
summary, our studies show that fibrate-mediated amelioration
of CP-induced ARF is accompanied by both peroxisome
proliferation as well as an increased expression of cytosolic
L-FABP in the proximal tubule. The finding of an increased
shedding of urinary h-L-FABP before serum creatinine rises
suggests that h-L-FABP could be considered as an early
biomarker of CP-mediated acute kidney injury.
MATERIALS AND METHODS
Animal model of CP-induced ARF
Experimental ARF was induced in 8-to 10-week-old male mice
(strain Sv129) using CP administration. The animals used in these
studies (IACUC protocol no. 2-03-1) were housed at the Veterinary
Medical Unit (Central Arkansas Veterans Health Care System, Little
Rock, AR, USA). When appropriate, animals were painlessly killed
according to methods of euthanasia approved by the Panel on
Euthanasia of the American Veterinary Medical Association. The
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group of sv129 mice used for these experiments were maintained on
standard chow and as indicated, a group of animals was fed with a
special diet containing fibrate compound WY-14643 (WY) (1% wt/
wt) for 7 days before the induction of ARF. CP was administered to
sv129 mice by a single intraperitoneal injection of 20 mg/kg body
weight. Engineering of h-L-FABP transgenic mice has been detailed
elsewhere.24 Briefly, genomic DNA of h-L-FABP, including its
promoter region (13 kb) was microinjected into fertilized eggs
obtained from C57/BL6 and CBA mice; ICR mice were used as
transfected-egg recipients. The resultant transgenic mice were
backcrossed for more than nine generations onto C57/BL6 mice
to obtain homozygous mutant mice on an inbred background. Only
heterozygous h-L-FABP transgenic mice were used in this experi-
ment. Male h-L-FABP transgenic mice weighing 25–30 g were fed
with standard chow diet or with a special diet containing Bz (0.5%
wt/wt) for 7 days before the induction of ARF. CP was administered
by a single intraperitoneal injection of 20 mg/kg body weight. After
the induction of renal failure, the animals were returned to their
cages and allowed free access to food and water. H-L-FABP
transgenic mice were kept in glass-shielded metabolic cages
(Metabolica; Sugiyamagen, Tokyo, Japan) until killing, and urine
was serially collected at each 24 h interval. To measure changes in
creatinine and BUN, blood was drawn from each tail vein at 0, 24,
48, and 72 h after CP administration. Serum creatinine was
measured using a combined enzymic-Jaffe method.42
Real-time quantitative reverse transcriptase-polymerase
chain reaction analysis
Mice were killed following previously described experimental
conditions, and the kidneys were rapidly snap-frozen in liquid
nitrogen and stored at 751C. Total RNA was extracted with TRIzol
Reagent (Invitrogen Corporation, Carlsbad, CA, USA) according to
the manufacturer’s directions. Total RNA extract was treated with
RQ1 RNase-free DNase (Promega Corporation, Madison, WI, USA)
before reverse transcription. Reverse transcription reaction was
performed at 421C for 50 min in a total volume of 20 ml containing
1 mg RNA, 0.5 mg of oligo (dT)12–18, 200 U of superscript II RNase
H reverse transcriptase (Invitrogen Life Technologies). Subse-
quently, reverse transcriptase was inactivated by incubation at
701C for 15 min, followed by treatment with RNase H at 371C for
30 min. Real-time polymerase chain reaction was performed using a
DNA Engine OPTICON 2 continuous fluorescence detector (MJ
Research Inc., Waltham, MA, USA) with SYBR Green I technology.
In each experiment, triplicates of 50 ng cDNA (total RNA
equivalent) of samples were amplified in a 50 ml reaction containing
1 iQTM SYBR Green Supermix (Bio-Rad Laboratories, Hercules,
CA, USA). The real-time polymerase chain reaction conditions are
1 cycle at 501C for 2 min followed by 1 cycle at 951C (10 min); 40
cycles at 951C (15 s), 611C (25 s), and 721C (16 s). Specificity of
the amplified product was confirmed by melting curve analysis.
For relative quantification, a standard curve was generated from a
six-step cDNA dilution series. Samples were amplified with primers
for mL-FABP and 28 s rRNA. The relative expression of mL-FABP
and 28 s rRNA were calculated from the standard curve. Relative
quantity was calculated by the ratio of mL-FABP and the appro-
priate 28 s rRNA expression. The primer sequences in the real time
reverse transcriptase-polymerase chain reaction were for mL-FABP
50-CATCAAAAGAGCCTGGGAAC-30 (forward), 50-ACACCCATACG
CCAACTCTT-30 (reverse) and 28 s rRNA 50-AACGGCGGGAG
TAACTATGA-30 (forward), 50-TAGGGACAGTGGGAATCTCG-30
(reverse).
Immunoblotting
Kidney tissue was homogenized in lysis buffer (50 mM Tris (pH 7.4),
100 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid, 1% Triton
X-100, 0.5% NP-40, 2.5 mM Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 25 mg/ml aprotinin and leupeptin, and 50 mg/ml Soybean
trypsin inhibitor) and sonicated briefly for 10 s subsequently
centrifuged at 11 000 g for 10 min at 41C, and the supernatant was
collected. Protein concentration was measured using the protein
assay kit (Bio-Rad Laboratories). Supernatants containing 50 mg of
protein were separated on a 12% sodium dodecylsulfate-polyacryl-
amide gel electrophoresis and then electroblotted to a nitrocellulose
membrane. The membrane was blocked for 1 h with 5% nonfat
dried milk in TBS-T buffer (20 mM Tris, pH 7.6, 100 mM NaCl, 0.1%
Tween 20). The primary antibodies used in our studies included
polyclonal L-FABP antibody (Hycult Biotechnology, Uden, The
Netherlands); rabbit anti-PMP70 antibody (Affinity Bioreagents,
Golden, CO, USA), and rabbit polyclonal catalase antibody
(Calbiochem, San Diego, CA, USA). These antibodies were used at
a 1:1000 dilution and membranes were incubated overnight in TBS-
T buffer containing 5% nonfat dried milk at room temperature.
After washing three times with TBS-T buffer, the membranes were
incubated with a horseradish peroxidase-conjugated goat anti-rabbit
IgG as a second antibody (1:5000 dilution) for 1 h at room
temperature. Proteins were visualized using by enzyme-linked
enhanced chemiluminescence (Amersham, Arlington Heights, IL,
USA). The membranes were stripped and then probed with b-actin
antibodies (Chemicon, Temecula, CA, USA) as an internal control.
Signals on the blots were visualized by autoradiography and
quantitated by densitometry using ImageQuant image analysis
system (Storm Optical Scanner; Molecular Dynamics, Sunnyvale,
CA, USA).
Tissue preparation for immunohistochemistry
Kidney tissue samples were obtained from control-, WY-, CP-, and
WYþCP-treated sv129 mice, and control-, CP-, Bz-, and BzþCP-
treated h-L-FABP transgenic mice. Tissues were fixed in 10%
neutral-buffered formalin and embedded in paraffin. Sections
(6mm) were placed on silane-coated slides (Sigma, St Louis, MO,
USA) and processed for morphologic analysis immunohistochem-
ical localization of PMP-70, L-FABP, and for immunofluorescent
staining of peroxisomes.
Morphologic analysis
Kidney sections were stained with PAS and the degree of
morphologic damage was determined using light microscopy. The
following parameters were graded to assess morphological damage
after CP and BzþCP treatment: brush border loss, red blood cell
extravasation, tubular dilatation, tubular degeneration, tubular
necrosis, tubular cast formation, interstitial edema, and inflamma-
tion. These parameters were evaluated on a scale of 0–4, which
ranged from not present (0), mild (1), moderate (2), severe (3), and
to very severe (4). Each parameter was determined at least on eight
different animals. Statistical significance was assessed by the two-
sided Student’s t-test for independent samples.
PMP70 and L-FABP immunohistochemistry
To further ascertain that CP or fibrate affect the expression of
PMP70, we performed immunostaining of mouse kidney tissue
treated with CP or fibrate using a rabbit anti-PMP70 antibody
(1:500 dilution; Affinity Bioreagents). In addition, since our Western
blot analysis suggested that fibrate increased the expression of
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L-FABP protein, we also performed immunostaining of mouse
kidney tissue using a L-FABP polyclonal antibody that recognized
mL-FABP (1:100 dilution; Hycult Biotechnology, Uden, The Nether-
lands), after which goat biotinylated anti-rabbit antibody (Vector
Laboratories Inc., Burlingame, CA, USA) and ABC Elite Vectastain
Kit (Vector Laboratories Inc.) was used. Nonspecific staining was
blocked with 5% normal goat serum (Sigma), and the sections were
permeabilized with 0.1% Triton X-100 (Sigma) and 0.05% saponin
(Sigma) digestion. Endogenous peroxidase was inactivated with 1%
hydrogen peroxide in phosphate-buffered saline/methanol (1:1).
Immunofluorescent staining of peroxisomes
To examine the effect of fibrate and CP on peroxisome proliferation
in kidney tissue, we used a novel method of immunofluorescent
labeling of peroxisomes, using an antibody to the PMP70, coupled
with fluorescent nanocrystals, Quantum Dots.24 This method is
applicable to standard formalin-fixed and paraffin-embedded
tissues. Paraffin sections were deparaffinized and hydrated in graded
alcohol series and distilled water. Endogenous biotin sites were
blocked by avidin/biotin blocking Kit (Vector Laboratories Inc.)
according to the manufacturer’s instructions. Nonspecific staining
was blocked with 10% normal goat serum. The sections were
incubated with rabbit anti-PMP70 antibody (diluted 1:500 in 10%
normal goat serum; Affinity Bioreagents) for 1 h, then washed in
phosphate-buffered saline and incubated for 30 min with (1:1000
dilution in phosphate-buffered saline) biotinylated goat anti-rabbit
IgG (Sigma). After washing three times in phosphate-buffered
saline, they were incubated with (1:100 dilution) 605 nm strepta-
vidin-coated Quantum Dots (Quantum Dot Corp., Hayward, CA,
USA). The sections were coverslipped and counterstained using
mounting media containing 4,6-diamidino-2-phenylindole (Vector
Laboratories Inc.). Fields for microscopic evaluation and subsequent
image analysis were selected randomly. Fluorescent images were
captured on a Zeiss LSM410 confocal microscope using a plan-
apochromat  63 oil immersion objective with 1.4 numerical
apertures. Blue, green, and red images were captured separately and
overlaid. 4,6-Diamidino-2-phenylindole and quantum dot 605
fluorophores were excited with a 405 diode laser. Red-orange
emitted light was detected after filtering with a 590–610 nm band
pass filter, 4,6-diamidino-2-phenylindole-emitted light was filtered
with a 435–485 nm band pass filter (D460/50m; Chroma Technology
Corporation., Rockingham, VT, USA), and green auto-fluorescence
was filtered through a 500–550 nm band pass filter (HQ525/50m;
Chroma). The pixel density of the quantum dot signals were
analyzed by Image J Software. Eight microscopic fields correspond-
ing to the cortex area on pairs of adjacent sections (four microscopic
fields/sections) from each animal kidney were chosen for area
imaging in each treatment group. We quantified the pixel intensity
of only orange/red color of quantum dot signals.
Measurement of urinary h-L-FABP protein
The enzyme-linked immunosorbent assay method for measuring
urinary h-L-FABP was reported previously.25,43,44 H-L-FABP protein
standard or 50 ml of urine samples obtained from h-L-FABP
transgenic mice are first treated with a pretreatment solution, and
then transferred into a 96-well plate coated with a monoclonal
antibody against h-L-FABP. After 1 h incubation, the wells are
washed and then the conjugate reagent is added as secondary
antibody for another hour allowing the binding of the h-L-FABP
antigen, the immobilized antibody and the conjugate antibody. After
incubation, the plate is washed and a substrate solution for the
immunoperoxidase reaction is added for 30 min to develop a color
based on the amount of h-L-FABP antigen present in the samples.
h-L-FABP concentration is measured by measuring the absorbance
of each well at 492 nm and calculated mass is determined based on a
calibration curve. Urinary h-L-FABP levels is expressed as the ratio
of the urinary h-L-FABP in micrograms to the urinary creatinine
level (mg).
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